NYSE - Delayed Quote USD

Nuvation Bio Inc. (NUVB)

4.7600 -0.0100 (-0.21%)

At close: October 30 at 4:00:03 PM EDT

4.7400 -0.0200 (-0.42%)

After hours: October 30 at 5:39:46 PM EDT

Trade NUVB on Coinbase

Chart Range Bar

Advanced Chart

AlphaSpace Chart

Loading chart for NUVB

30m ago Powered by Yahoo Scout

Nuvation Bio is expanding the global Phase 3 SIGMA study for safusidenib, adding six European countries to its trial network. The company also has commercial momentum from IBTROZI, while its upcoming November 4, 2026 earnings updatewill provide the next major readout on finances and pipeline progress.

Previous Close 4.7700
Open 4.7500
Bid 4.7100 x 970000
Ask 4.7300 x 1250000
Day's Range 4.6000 - 4.8050
52 Week Range 3.9200 - 9.7500
Volume 5,059,887
Avg. Volume 5,351,581
Market Cap (intraday) 1.671B
Beta (5Y Monthly) 1.62
PE Ratio (TTM) --
EPS (TTM) -0.4400
Earnings Date Nov 4, 2026
Forward Dividend & Yield -- (0.00%)
1y Target Est 13.00
Zacks Rating Neutral

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

www.nuvationbio.com

305

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NUVB

46.87%

S&P 500 (^GSPC)

10.73%

1-Year Return

NUVB

7.57%

S&P 500 (^GSPC)

11.11%

3-Year Return

NUVB

376.00%

S&P 500 (^GSPC)

81.91%

5-Year Return

NUVB

48.09%

S&P 500 (^GSPC)

64.59%

Earnings Per Share

gaap GAAP

nongaap Normalized

gaap GAAP

nongaap Normalized

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q2 FY26

Revenue 31.69M

Earnings -62.84M

Profit Margin -198.31%

FY25

FY26

-50M

50M

-400.0%

-300.0%

-200.0%

-100.0%

0.0%

Analyst Price Targets

7.00

13.00 Average

4.7600 Current

21.00 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Latest Rating

Date 9/30/2026

Analyst Citigroup

Rating Action Initiated

Rating Buy

Price Action Announces

Price Target 12

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

-88.19%
Return on Assets (ttm)

-12.36%
Return on Equity (ttm)

-47.81%
Revenue (ttm)

169.9M
Net Income Avi to Common (ttm)

-149.83M
Diluted EPS (ttm)

-0.4400

Balance Sheet and Cash Flow

Total Cash (mrq)

660.96M
Total Debt/Equity (mrq)

163.97%
Levered Free Cash Flow (ttm)

-112.11M

LYEL

TSHA

STOK

OLMA

ANNX

U.S. markets closed

Nuvation Bio Inc. (NUVB)

Trading disclosure

4.16%

-15.00%

6.97%

-46.87%

-7.57%

-48.09%

-52.87%

What's happening with NUVB?

Nuvation Bio Inc. Overview Biotechnology / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Latest Rating

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch